The abstract is read at the publisher; the summary is JClub's.
DreAM-plus, a multilayer RNA switch for AAV, enables transient expression of multiple gene editors with <24 h temporal resolution and reduces off-target effects by 1.4–2.8-fold.
- Why it matters: Long-term AAV expression can increase off-target activity and immunogenicity, so drug-inducible systems are needed to tightly control gene editor exposure over time.
- What they did: The authors combined an aptamer-based poly(A) regulator (pA), the drug-elicitable DreAM splicing module, and an engineered P2A with conditional upstream open reading frames (uORFs) to build DreAM-plus. Inducibility improved up to 5-fold versus pA or DreAM alone, with an additional 1.4–6.3-fold gain from uORFs.
- The result: In mice with lipid-nanoparticle-delivered pre-existing immunity, DreAM-plus attenuated AAV-delivered Cas-specific CD8+ T cell immune toxicity in liver and heart, while also mitigating off-target effects by 1.4–2.8-fold.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.